wowjili code
How to optimise your tech resume for your next job in 2025
Snowy owl rescued from car grille by Minnesota woman who saved another bird hours earlier
November 24 - On Saturday, the Tampa Bay Lightning faced a club they met in a recent Stanley Cup Final when they played against the Dallas Stars. They get a chance to do so again to start Thanksgiving week when the Lightning play host the Colorado Avalanche on Monday night. While Tampa Bay did get past the Stars to win the title in 2020, coach Jon Cooper's team was unable to fight through injuries in the 2022 Final that slipped away to the Avalanche in six games. Offensive spark plug Brayden Point missed most all of that postseason. The 13th-year Lightning coach is combatting new enemies these days. "One team tried to make six passes and put the puck in the net and turned it over, and the other team made two passes and threw it in the net," Cooper said after Saturday's 4-2 home loss, while comparing his team to the Stars. "One team waited for the other team to make a mistake, they did, and that team capitalized on it. That was it. "We blinked first and we lost." The Lightning's Anthony Cirelli scored twice and extended his goal streak to five games, but Dallas forward Matt Duchene broke a 2-2 tie in the third period and Roope Hintz scored 58 seconds later to sink the Lightning and drop them to 3-4-2 in November. Cooper's frustrations in his group's pass-first play have been noted, but they seemed to reach a boiling point after a second straight setback. "It's almost like the goals don't count unless they make the highlight reel," Cooper said. "We haven't quite figured out that if the puck just crosses the goal line in between the pipes, it counts. It doesn't have to be an all-world play." As they get healthier, the Avalanche demonstrated Saturday against the defending Stanley Cup champions that they have no problem scoring. Mikko Rantanen notched a goal and three assists as Colorado powered past the Florida Panthers in a 7-4 victory. Wingers Valeri Nichushkin (suspension) and Jonathan Drouin (upper-body injury) were playing their fourth games since returning from season-long absences and had their best showings so far. A power forward, Nichushkin notched a goal and two assists, while the slick Drouin scored twice, the first tallies for each this season. Drouin was injured six weeks ago on opening night while playing left wing on the top line against the Vegas Golden Knights and missed 16 games. He said he and his teammates followed the lead of the champion Panthers. "I thought we played well after giving up that first goal," Drouin said. "We tried to play a little how they do: Put the puck in deep, try to make them come 200 feet to our net. I don't think we made many mistakes in that game." The Avalanche are on a three-game winning streak and are 7-3-0 this month. That surge has them in fourth place in the Central Division behind the first-place Winnipeg Jets, Minnesota Wild and Stars, respectively. Colorado turned defense into offense in the win. "We shut down the rush attack and that is important to get above them because they are a dangerous rush team," Avalanche coach Jared Bednar said. "They push north hard. For most of the game, we did a real good job of that. Our defensive play led to good offense." --Field Level Media Our Standards: The Thomson Reuters Trust Principles. , opens new tab
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced that it intends to offer and sell common shares (the “Common Shares”) in an underwritten public offering (the “Offering”). In addition, Profound expects to grant the underwriters of the Offering a 30-day option to purchase up to an additional 15% of the Common Shares sold in the Offering. All of the securities in the Offering are being offered by Profound. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The net proceeds of the Offering are expected to be used: (i) to fund the continued commercialization of the TULSA-PRO® system in the United States, (ii) to fund the continued development and commercialization of the TULSA-PRO® system and the Sonalleve® system globally, and (iii) for working capital and general corporate purposes. The Offering is expected to be completed pursuant to an underwriting agreement to be entered into between the Company and Raymond James Ltd. and Lake Street Capital Markets as co-lead underwriters and joint bookrunners, and a third underwriter. The Offering is expected to take place in each of the provinces and territories of Canada, except the province of Québec, and in the United States. The Offering is expected to close on or about December 10, 2024, subject to customary closing conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Toronto Stock Exchange. Profound will notify the Nasdaq Capital Market in accordance with the rules of that exchange. In connection with the Offering, the Company has filed a preliminary prospectus supplement (the “Preliminary Prospectus Supplement”) and intends to file a subsequent prospectus supplement (the “Prospectus Supplement”) to its short form base shelf prospectus dated July 10, 2024 (the “Base Shelf Prospectus”) in each of the provinces and territories of Canada relating to the proposed Offering. The Prospectus Supplement will also be filed in the United States with the U.S. Securities and Exchange Commission (the “SEC”) as part of the Company’s effective registration statement on Form F-10 (File no. 333-280236), as amended, previously filed under the multijurisdictional disclosure system adopted by the United States. Access to the Base Shelf Prospectus, the Prospectus Supplement, and any amendments to the documents will be provided in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment. The Base Shelf Prospectus is, and the Prospectus Supplement will be (within two business days of the date hereof), accessible on SEDAR+ at www.sedarplus.com and on EDGAR at www.sec.gov . The Common Shares are offered under the Prospectus Supplement. An electronic or paper copy of the Base Shelf Prospectus, the Prospectus Supplement (when filed), and any amendment to the documents may be obtained without charge, from Raymond James Ltd., Scotia Plaza, 40 King St. W., 54th Floor, Toronto, Ontario M5H 3Y2, Canada, or by telephone at 416-777-7000 or by email at ECM-Syndication@raymondjames.ca by providing the contact with an email address or address, as applicable. Copies of the Prospectus Supplement and the Base Shelf Prospectus will be available on EDGAR at www.sec.gov or may be obtained without charge from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at prospectus@raymondjames.com , and from Lake Street Capital Markets, LLC, 920 2nd Ave S - Ste 700, Minneapolis, MN 55402, prospectus@lakestreetcm.com , (612) 326-1305. The Base Shelf Prospectus and Prospectus Supplement contain important, detailed information about the Company and the proposed Offering. Prospective investors should read the Base Shelf Prospectus and Prospectus Supplement (when filed) before making an investment decision. No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, territory, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, territory, state or jurisdiction. About Profound Medical Corp. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Forward-Looking Statements This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the Offering, including the Offering’s timing, pricing, underwriters, size, terms, selling jurisdictions, closing, over-allotment option, and use of proceeds; the availability and timing of the final prospectus supplement; and, the expectations regarding the efficacy and commercialization of Profound’s technology. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Additional information about the risks and uncertainties of forward-looking statements and the assumptions upon which they are based is contained in the Company’s filings with securities regulators, which are available electronically through SEDAR+ at www.sedarplus.com and EDGAR at www.sec.gov . Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law. For further information, please contact: Stephen Kilmer Investor Relations skilmer@profoundmedical.com T: 647.872.4849NoneSportswatch Daily Listings